X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (174) 174
humans (165) 165
pulmonary hypertension (130) 130
cardiac & cardiovascular systems (105) 105
female (98) 98
male (96) 96
hypertension, pulmonary - drug therapy (78) 78
middle aged (76) 76
hypertension (68) 68
respiratory system (66) 66
treatment outcome (64) 64
abridged index medicus (62) 62
adult (61) 61
hypertension, pulmonary - physiopathology (59) 59
pulmonary arterial hypertension (54) 54
aged (46) 46
hypertension, pulmonary - diagnosis (42) 42
double-blind method (41) 41
drug therapy (40) 40
therapy (38) 38
survival (37) 37
antihypertensive agents - therapeutic use (34) 34
diagnosis (32) 32
hypertension, pulmonary - therapy (32) 32
care and treatment (31) 31
cardiovascular (30) 30
hypertension, pulmonary - etiology (30) 30
bosentan (29) 29
double-blind (29) 29
pulmonary arteries (28) 28
mortality (26) 26
prognosis (26) 26
endothelin receptor antagonists (23) 23
endothelin (22) 22
cardiology and cardiovascular medicine (21) 21
continuous intravenous epoprostenol (21) 21
guidelines (21) 21
prostacyclin (21) 21
clinical trials (20) 20
dose-response relationship, drug (20) 20
heart failure (20) 20
inhaled iloprost (20) 20
risk factors (20) 20
sildenafil (20) 20
sulfonamides - therapeutic use (20) 20
cardiology (19) 19
follow-up studies (19) 19
hemodynamics - drug effects (19) 19
hypertension, pulmonary - mortality (19) 19
research (19) 19
algorithms (18) 18
analysis (18) 18
disease (18) 18
hypertension, pulmonary - complications (18) 18
internal medicine (18) 18
medicine, general & internal (18) 18
drug therapy, combination (17) 17
exercise (17) 17
hypertension, pulmonary - epidemiology (17) 17
patients (17) 17
registry (17) 17
vasodilator agents - therapeutic use (17) 17
adolescent (16) 16
disease progression (16) 16
familial primary pulmonary hypertension (16) 16
pulmonary/respiratory (16) 16
surgery (16) 16
critical care medicine (15) 15
exercise tolerance - drug effects (15) 15
pulmonary (15) 15
pulmonary embolism (15) 15
time factors (15) 15
administration, oral (14) 14
antihypertensive agents - administration & dosage (14) 14
brain natriuretic peptide (14) 14
congenital heart disease (14) 14
hemodynamics (14) 14
heart (13) 13
lung transplantation (13) 13
prospective studies (13) 13
sildenafil citrate (13) 13
animals (12) 12
endothelin-receptor antagonist (12) 12
epoprostenol (12) 12
exercise test (12) 12
hypertension, pulmonary (12) 12
placebo-controlled trial (12) 12
quality of life (12) 12
young adult (12) 12
antihypertensive agents - adverse effects (11) 11
cardiac patients (11) 11
dosage and administration (11) 11
drug administration schedule (11) 11
echocardiography (11) 11
medical colleges (11) 11
medicine & public health (11) 11
pharmacology & pharmacy (11) 11
prostacyclin analog (11) 11
prostanoids (11) 11
risk assessment (11) 11
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (336) 336
Spanish (16) 16
Italian (13) 13
Turkish (6) 6
Polish (4) 4
Portuguese (3) 3
Romanian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 834 - 844
Patients with previously untreated pulmonary arterial hypertension who were randomly assigned to combination therapy with ambrisentan and tadalafil had a... 
INHALED ILOPROST | SURVIVAL | TRIAL | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | EPOPROSTENOL | COMBINATION THERAPY | HEART-FAILURE | DOUBLE-BLIND | BOSENTAN | Hypertension, Pulmonary - mortality | Double-Blind Method | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Hypertension, Pulmonary - physiopathology | Male | Hospitalization | Disease Progression | Tadalafil | Phenylpropionates - therapeutic use | Peptide Fragments - blood | Adult | Female | Phenylpropionates - adverse effects | Aged | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Natriuretic Peptide, Brain - blood | Pyridazines - adverse effects | Pyridazines - therapeutic use | Symptomatology | Care and treatment | Usage | Analysis | Clinical trials | Dosage and administration | Pulmonary hypertension | Ambrisentan | Hypertension | Edema | Brain natriuretic peptide | Headache | Functional morphology | Pulmonary arteries | Lung diseases | Drug therapy | Patients | Clinical outcomes | Index Medicus | Abridged Index Medicus | Drug side effects | Assaigs clínics de medicaments | Efectes secundaris dels medicaments | Hipertensió pulmonar | Drug testing | Life Sciences | Human health and pathology | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 26, pp. 2522 - 2533
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 12, pp. 1536 - 1544
Abstract Background The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown. Objectives This study investigated the long-term... 
Cardiovascular | Internal Medicine | chronic thromboembolic pulmonary hypertension | thrombolysis | long-term survival | pulmonary embolism | prognosis | DIAGNOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | GUIDELINES | CARDIOLOGY ESC | EUROPEAN-SOCIETY | TIME TRENDS | TRIAL | TASK-FORCE | HYPERTENSION | Pulmonary Embolism - prevention & control | Echocardiography | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Tissue Plasminogen Activator - therapeutic use | Pulmonary Embolism - mortality | Fibrinolytic Agents - therapeutic use | Thrombolytic Therapy | Aged, 80 and over | Female | Aged | Tenecteplase | Pulmonary Embolism - diagnostic imaging | Pulmonary embolism | Stroke (Disease) | Medicine, Experimental | Medical research | Cardiology | Cardiovascular agents | Heart | Therapy | Chest | Lung | Incidence | Design | Computed tomography | Motivation | Tomography | Diagnosis | Thromboembolism | Anticoagulants | Pulmonary arteries | Mortality | Statistical tests | Patients | Fibrinolysis | Survival | Computation | Diagnostic software | Death | Health risk assessment | Risk management | Angiography | Arches | Embolisms | Medical services | Clinical trials | Population studies | Hemorrhage | Bleeding | Guidelines | Reperfusion | Risk assessment | Calcium-binding protein | Trends | Heart diseases | Injuries | Hypertension | Collapse | Stroke | Statistical analysis | Receiving | Steering | Complications | Risk reduction | Statistics | Pulmonary hypertension | Embolism | Computer programs | Contact | Thromboplastin | Medical prognosis | Fatalities | Ventricle | Heparin | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2009, Volume 54, Issue 21, pp. 1971 - 1981
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 4, pp. 330 - 340
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 15, pp. 1402 - 1411
In a randomized trial, 1006 patients with intermediate-risk pulmonary embolism were assigned to tenecteplase or placebo in addition to standard heparin... 
MEDICINE, GENERAL & INTERNAL | MANAGEMENT | VENOUS THROMBOEMBOLISM | ELEVATION | COMPLICATIONS | ECHOCARDIOGRAPHY | THROMBOLYTIC THERAPY | RIGHT-VENTRICULAR ENLARGEMENT | PROGNOSTIC ROLE | Pulmonary Embolism - complications | Age Factors | Double-Blind Method | Humans | Middle Aged | Risk Factors | Heparin - therapeutic use | Male | Treatment Outcome | Tissue Plasminogen Activator - therapeutic use | Heparin - adverse effects | Tissue Plasminogen Activator - adverse effects | Pulmonary Embolism - mortality | Fibrinolytic Agents - adverse effects | Stroke - chemically induced | Fibrinolytic Agents - therapeutic use | Ventricular Dysfunction, Right - etiology | Aged, 80 and over | Troponin - blood | Female | Pulmonary Embolism - drug therapy | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Pulmonary embolism | Evaluation | Usage | Care and treatment | Fibrinolysis | Heart | Stroke | Heart attacks | Echocardiography | Embolisms | Pulmonary arteries | Lung | Hemorrhage | Bleeding | Embolism | Blood clots | Troponin T | Fibrin | Troponin | Troponin I | Motivation | Computed tomography | Ischemia | Calcium-binding protein | Heparin | Ventricle | Drug therapy | Index Medicus | Abridged Index Medicus | Ventricular Dysfunction, Right | Fibrinolytic Agents | Life Sciences | Tissue Plasminogen Activator | Pulmonary Embolism
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 9, pp. 809 - 818
Journal Article